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Full Disclosure—Nothing Less Will Do
It is with some trepidation that I offer a coun-terpoint to such a distinguished editor and Harvard cancer professor. In his editorial in 
this issue, Thomas Stossel (2007) writes clev-
erly, although predictably (Stossel, 1999, 2005) 
and, as I shall argue, speciously. His commen-
tary is to be welcomed because conflicts of 
interest (COI) are rarely discussed in the derma-
tology literature (Williams et al., 2006), and I 
thank the Journal of Investigative Dermatology 
for allowing me an opportunity to explore some 
of Stossel’s key concerns.
I strongly urge JID readers to read the original 
article for themselves (Williams et al., 2006), 
because Stossel misunderstands two crucial 
points. He begins by obfuscating the differ-
ences between a circumstance and a behavior 
(Smith, 2006). We defined a competing inter-
est as one in which professional judgment 
concerning a primary interest (such as the care 
of patients) could be influenced by a second-
ary interest (such as financial gain). This does 
not mean that everyone with such a secondary 
interest then sets out to deliberately deceive 
their audience about their research—most do 
not and some might overcompensate for such 
COI. A COI simply means that a set of condi-
tions is operating that could have a marked 
influence on behavior. It is for the audience 
and not the researcher to make a judgment on 
whether such conflicts are relevant and whether 
the condition could have resulted in a specific 
behavior. Most journals restrict their declaration 
of conflicts to financial ones simply because 
they are clear and easier to describe (Smith, 
2006; Caplan, 2007). Here I completely agree 
with Stossel that it makes little sense to include 
only financial interactions that involve drug or 
device companies—the JID certainly makes 
no such distinction on financial conflicts in its 
COI policy (http://www.nature.com/jid/author_
instructions.html; accessed 24 April 2007). Nor 
does the Journal of Clinical Investigation—a 
leading journal of which Stossel was formerly 
Chief Editor and one that has recently under-
taken stringent measures to develop clear and 
comprehensive policies on COI that extend to 
editors and referees as well as authors (Neill et 
al., 2007).
Stossel then polarizes the debate into one 
of clinicians versus industry—a dichotomy 
that we strove to avoid, given that conflicts of 
interest can occur for all sorts of reasons, such 
as ambition, rivalry, and envy (Caplan, 2007). 
But since he has mentioned the pharmaceuti-
cal industry, it is an uncomfortable fact that 
some of the most obscene conflicts and behav-
iors have come from that sector, as summa-
rized in a detailed House of Commons enquiry 
(House of Commons Health Committee, 2005). 
Just recently I read the gory details of the rofe-
coxib (Vioxx) affair stemming from the VIGOR 
study—of a promising new drug that resulted 
in serious cardiovascular harm—and how con-
flicting interests among Merck’s board mem-
bers had complicated matters (Krumholz et al., 
2007). The head of the VIGOR trial board, for 
example, had family ownership in Merck shares 
worth $70,000, which was not a matter of pub-
lic record when the trial was conducted or pub-
lished. Perhaps the conflict had nothing to do 
with the concealed cardiovascular risk in the 
publication—the main point is that it was not 
declared. What surprised me most was not that 
the Vioxx scandal occurred but how little the 
medical community seemed to react. Winston 
Churchill described the phenomenon aptly: 
“Men occasionally stumble over the truth, but 
most of them pick themselves up and hurry off 
as if nothing ever happened.” I also do not agree 
with Stossel that most advances in medicine and 
dermatology are due to “products developed 
by private companies.” Of course, our patients 
have benefited greatly from some treatments, 
such as topical corticosteroids, oral and topical 
retinoids, and (possibly) the new biologics for 
psoriasis, but other advances, such as identify-
ing the causative agents for infectious and non-
communicable skin diseases, studies of disease 
definition, outcome assessment, and prognosis, 
treatments such as ultraviolet light, and preven-
tion of skin diseases such as melanoma, have 
not come primarily from private companies.
Stossel then dismisses the BMJ surveys of the 
effects of declaring COI, but does not suggest 
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a better scientific way to explore such effects. The litera-
ture is replete with clear evidence of the potential harms of 
COI, including reporting outcomes that were not part of the 
original protocol (Chan and Altman, 2005), selective report-
ing of positive results and positive studies (Melander et al., 
2003), duplicate publication (von Elm et al., 2004), and 
ghost writing (Gotzsche et al., 2007)—what more do we 
need to convince us that steps need to be taken to ensure 
that trial protocols are registered and reported properly with 
full declarations of COI? Stossel also dismisses the contribu-
tion of “unconflicted” researchers and equates them with 
being less competent based on one anecdote, yet there are 
plenty of examples of “unconflicted” individuals working in 
independent organizations such as the UK National Institute 
for Health and Clinical Excellence (http://www.nice.org.uk) 
and the US Agency for Healthcare Research and Quality 
(http://www.ahrq.gov/) who produce excellent, insightful, 
and accurate research summaries that minimize bias.
The question remains as to whether COI is a problem in 
dermatology. I cannot think of any logical reason why those 
of us in dermatology should be exempt from human nature. 
Money makes the world go round, and the sums of money 
involved in drug-company research are vast. I agree with 
Rees, who commented recently in this journal on “how eas-
ily our quest for truth is subverted” (Rees, 2007). The point 
is that the extent and effects of COI in dermatology have 
been studied very little to date (Williams et al., 2006). Perlis 
et al. (2005) have documented that 43% of 179 dermato-
logical clinical trials reported financial conflicts for at least 
one author and that such studies were more likely to report 
positive results than others. Schemes that allow pharmaceu-
tical funding of U.S. dermatology trainee programs have 
also raised concerns that they might lead to significant con-
flicts of interest (Kuehn, 2005). Katz and Bartus have drawn 
attention to misleading advertisements in dermatology 
journals and inconsistent or absent policies governing such 
advertisements (Katz, 2005; Bartus and Katz, 2006). Others 
have tried to develop voluntary codes of practice to manage 
COI in dermatology (Prendergast et al., 2004). We may not 
have any Vioxx scandals yet, but maybe it is only a matter of 
time—the story of evening primrose oil for atopic eczema 
came quite close (Williams, 2003).
So where do I stand in all this? It is important that we 
remember what the whole debate is about—it is not about 
me or Stossel or doctors or industry, but about patients’ wel-
fare. Distortions of the scientific record result in wasted time 
for patients and doctors (Chalmers, 2006). Scarce resources 
can be misspent denying others appropriate treatments, and 
sometimes bias results in downright harm, as in the Vioxx 
affair (Krumholz et al., 2007). If, as Stossel suggests, start-up 
companies in his area of the United States are genuinely sti-
fled because of overregulation, then he has my sympathies. 
As noted in Lowell Goldsmith’s recent JID editorial about 
COI (Goldsmith, 2006), we need a balance in such matters, 
and maybe regulation has swung too far in Stossel’s patch. I 
also have some sympathies with Stossel’s view that declar-
ing COI can be perceived as a discredit rather than honor 
of sponsorship, yet I fail to see how any scientist can argue 
against full disclosure in this day and age. So, do I encour-
age investigator-led studies with industry colleagues? Yes. 
Encourage interactions between universities and industry that 
lead to better health and wealth? A resounding yes. But as 
for the failure to permit readers and editors access to original 
trial protocols in the public domain (Dellavalle et al., 2007), 
failure to disclose potential conflict of interest in dermatol-
ogy presentations and publications, and failure to report all 
the data honestly and completely—no compromises.
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